Sort   by:  
 Page size 
MetabolomicsMetabolomics of human primary B-ALL cells treated by BCR-Abl1 inhibitor, STI571, and p190 BCR-Abl+ BAF3 cells with ASS1 knockdown
Analyze the Metabolomics changes in B-ALL cells after the treatment of imatinib and p190+ BAF3 cells with ASS1 knockdown or left untreated. two methods as the below LC-MS description showed were used.
2026-07-08 | MTBLS14638 | MetaboLights
TranscriptomicsEfficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia
Alterations of IKZF1, encoding the lymphoid transcription factor IKAROS, are a hallmark of high risk acute lymphoblastic leukemia (ALL), however the role of IKZF1 alterations in ALL pathogenesis is poorly understood. Here we show that in mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations s...
ORGANISM(S): Mus musculus 
2015-09-04 | E-GEOD-68391 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human BCR-ABL1-transformed acute lymphoblastic leukemia cells reveals Activation-induced cytidine deaminase acts as a mutator
The Philadelphia chromosome (Ph) encoding the oncogenic BCR-ABL1 kinase defines a subset of ALL with a particularly unfavorable prognosis. Acute lymphoblastic leukemia (ALL) cells are derived from B cell precursors in most cases and typically carry rearranged immunglobulin heavy chain (IGH) variable...
ORGANISM(S): Homo sapiens 
2008-06-15 | E-GEOD-7182 | biostudies-arrayexpress
ProteomicsSFPQ-ABL1 and BCR-ABL1 utilise different signalling networks to drive B-cell acute lymphoblastic leukaemia
Philadelphia-like (Ph-like) acute lymphoblastic leukaemia (ALL) is a high-risk subtype of B-cell ALL characterised by a gene expression profile resembling Philadelphia Chromosome positive ALL (Ph+ ALL) in the absence of BCR-ABL1. Tyrosine kinase activating fusions, some involving ABL1, are recurrent...
ORGANISM(S): Mus musculus (Mouse) 
2022-05-20 | PXD028925 | Pride
Abl1 Sfpq Bcr Leukaemia Aml 
TranscriptomicsBCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein
Coordinated BCR-ABL1 kinase-dependent and -independent mechanisms convert p27 from a nuclear tumor suppressor to a cytoplasmic oncogene. Persistence of oncogenic p27 functions despite effective inhibition of BCR-ABL1 may contribute to resistance to tyrosine kinase inhibitors. BCR-ABL1 induced p27 ve...
ORGANISM(S): Mus musculus 
2014-10-08 | E-GEOD-59168 | biostudies-arrayexpress
Transcriptomicsgamma-catenin (junction plakoglobin, Jup) dependent signals mediate the progression of BCR-ABL1+ B-ALL
The BCR-ABL1 translocation product is the cause of Chronic Myeloid Leukemia (CML) and of a significant fraction of adult-onset B-Acute Lymphoblastic Leukemia (B-ALL) cases. Here we identify an essential role for gamma-catenin (junction plakoglobin) in B lineage restricted cells for the progression o...
ORGANISM(S): Mus musculus 
2014-02-08 | E-GEOD-54793 | biostudies-arrayexpress
TranscriptomicsGene expression data of BCR-ABL1 transformed B cell precursors from BCL6 wild-type and BCL6 knockout mice
To elucidate the mechanism of BCL6-mediated pre-B cell survival signaling, we investigated the gene expression pattern in BCR-ABL1-transformed BCL6+/+ and BCL6-/- B cell precursors. Pharmacological inhibition of BCR-ABL1 was performed with the BCR-ABL1 kinase inhibitor STI571 (Imatinib). BCR-ABL1 t...
ORGANISM(S): Mus musculus 
2010-05-27 | E-GEOD-20987 | biostudies-arrayexpress
TranscriptomicsExploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
In this study, using a murine model of Ph+ acute lymphoblastic leukemia (Ph+ ALL), a combined pharmacological profile and drug selection experimental approach identified distinct stages of tumor clonal evolution with vulnerabilities to sets of small molecules. Through genotypic, phenotypic, signalin...
ORGANISM(S): Mus musculus 
2016-04-05 | E-GEOD-72910 | biostudies-arrayexpress
GenomicsTranscriptomic classes of BCR-ABL1 lymphoblastic leukemia
In BCR-ABL1 lymphoblastic leukemia, treatment heterogeneity to tyrosine kinase inhibitors (TKIs), especially in the absence of kinase domain mutations in BCR-ABL1, is poorly understood. Through deep molecular profiling, we uncovered three transcriptomic subtypes of BCR-ABL1 lymphoblastic leukemia, e...
EGAS00001007167 | EGA
ProteomicsDevelopment of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase
Mirror-image proteins, composed of D-amino acids, are an attractive therapeutic modality, as they exhibit high metabolic stability and lack immunogenicity. Development of mirror-image binding proteins is achieved through chemical synthesis of D-target proteins, phage display library selection of L-b...
ORGANISM(S): Homo sapiens (Human) 
2024-10-28 | PXD056009 | Pride
Monobodies Oncogenic bcr::abl1 kinase Mirror-image-monobodies 
Sort   by:  
 Page size